Key result
Neonatal CPC exosomes improve post-MI ejection fraction without requiring hypoxia, outperforming older pediatric cells.
Why the study?
Do human pediatric cardiac progenitor cell-derived exosomes improve cardiac function in a rat model of ischemia-reperfusion injury?
Do human pediatric cardiac progenitor cell-derived exosomes improve cardiac function in a rat model of ischemia-reperfusion injury?
This preclinical study demonstrates that donor age and oxygen content in the microenvironment significantly alter the efficacy of human CPC-derived exosomes for cardiac repair post-myocardial infarction.
Answers are grounded in this paper and cite their sources.
Should not yet alter post-MI care; hypothesis-generating for age- and hypoxia-dependent CPC exosome efficacy.
RATIONALE: Studies have demonstrated that exosomes can repair cardiac tissue post-myocardial infarction and recapitulate the benefits of cellular therapy. OBJECTIVE: We evaluated the role of donor age and hypoxia of human pediatric cardiac progenitor cell (CPC)-derived exosomes in a rat model of ischemia-reperfusion injury. METHODS AND RESULTS: Human CPCs from the right atrial appendages from children of different ages undergoing cardiac surgery for congenital heart defects were isolated and cultured under hypoxic or normoxic conditions. Exosomes were isolated from the culture-conditioned media and delivered to athymic rats after ischemia-reperfusion injury. Echocardiography at day 3 post-myocardial infarction suggested statistically improved function in neonatal hypoxic and neonatal normoxic groups compared with saline-treated controls. At 28 days post-myocardial infarction, exosomes derived from neonatal normoxia, neonatal hypoxia, infant hypoxia, and child hypoxia significantly improved cardiac function compared with those from saline-treated controls. Staining showed decreased fibrosis and improved angiogenesis in hypoxic groups compared with controls. Finally, using sequencing data, a computational model was generated to link microRNA levels to specific outcomes. CONCLUSIONS: CPC exosomes derived from neonates improved cardiac function independent of culture oxygen levels, whereas CPC exosomes from older children were not reparative unless subjected to hypoxic conditions. Cardiac functional improvements were associated with increased angiogenesis, reduced fibrosis, and improved hypertrophy, resulting in improved cardiac function; however, mechanisms for normoxic neonatal CPC exosomes improved function independent of those mechanisms. This is the first study of its kind demonstrating that donor age and oxygen content in the microenvironment significantly alter the efficacy of human CPC-derived exosomes.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2016) studied Myocardial ischemia-reperfusion injury. Human pediatric cardiac progenitor cell (CPC)-derived exosomes (cultured under normoxic or hypoxic conditions) vs. Saline-treated ischemia-reperfusion controls was evaluated on Left ventricular ejection fraction (EF) at day 3 and day 28 post-ischemia-reperfusion (p=<0.05). Neonatal cardiac progenitor cell-derived exosomes significantly improved rat post-MI ejection fraction at 28 days regardless of oxygen culture conditions, whereas infant and child exosomes required hypoxia.
Synapse has enriched 10 related papers. Consider them for comparative context: